Palatin Technologies Net Income 2006-2021 | PTN

Palatin Technologies net income from 2006 to 2021. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Palatin Technologies Annual Net Income
(Millions of US $)
2021 $-34
2020 $-22
2019 $36
2018 $25
2017 $-13
2016 $-52
2015 $-18
2014 $-14
2013 $-21
2012 $-17
2011 $-13
2010 $-2
2009 $-5
2008 $-14
2007 $-28
2006 $-29
2005 $-14
Palatin Technologies Quarterly Net Income
(Millions of US $)
2021-06-30 $-14
2021-03-31 $-6
2020-12-31 $-10
2020-09-30 $-4
2020-06-30 $-7
2020-03-31 $-5
2019-12-31 $-5
2019-09-30 $-5
2019-06-30 $52
2019-03-31 $-6
2018-12-31 $-5
2018-09-30 $-6
2018-06-30 $12
2018-03-31 $-1
2017-12-31 $3
2017-09-30 $11
2017-06-30 $13
2017-03-31 $-4
2016-12-31 $-10
2016-09-30 $-13
2016-06-30 $-13
2016-03-31 $-13
2015-12-31 $-13
2015-09-30 $-12
2015-06-30 $-12
2015-03-31 $-9
2014-12-31 $3
2014-09-30 $1
2014-06-30 $-4
2014-03-31 $-2
2013-12-31 $-4
2013-09-30 $-4
2013-06-30 $-5
2013-03-31 $-4
2012-12-31 $-2
2012-09-30 $-10
2012-06-30 $-5
2012-03-31 $-6
2011-12-31 $-3
2011-09-30 $-3
2011-06-30 $-3
2011-03-31 $-4
2010-12-31 $-1
2010-09-30 $-5
2010-06-30 $-4
2010-03-31 $-2
2009-12-31 $5
2009-09-30 $-0
2009-06-30 $-0
2009-03-31 $0
2008-12-31 $-0
2008-09-30 $-4
2008-06-30 $-5
2008-03-31 $-5
2007-12-31 $-4
2007-09-30 $-0
2007-06-30 $-6
2007-03-31 $-7
2006-12-31 $-6
2006-09-30 $-8
2006-06-30 $-8
2006-03-31 $-8
2005-12-31 $-7
2005-09-30 $-6
2005-06-30 $-5
2005-03-31 $-4
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.097B $0.000B
Palatin Technologies, Inc is a development-stage medical technology companyinvolved in developing and commercializing products and technologies fordiagnostic imaging, cancer therapy and ethical drug development These developments are based on its proprietary monoclonal antibody radiolabeling and enabling peptide platform technologies.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $125.527B 7.92
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.184B 20.63
Biohaven Pharmaceutical Holding (BHVN) United States $8.967B 0.00
Emergent Biosolutions (EBS) United States $2.590B 6.25
Arcus Biosciences (RCUS) United States $2.362B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.929B 0.00
Myovant Sciences (MYOV) United Kingdom $1.832B 0.00
Zymeworks (ZYME) Canada $1.055B 0.00
Ambrx Biopharma (AMAM) United States $0.463B 0.00
SQZ Biotechnologies (SQZ) United States $0.372B 0.00
Enzo Biochem (ENZ) United States $0.159B 15.67